Yago Nieto

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint High-dose chemotherapy for breast cancer: is another look warranted?
    Yago Nieto
    Blood and Marrow Transplant Program, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B 190 Denver, CO 80262, USA
    Curr Opin Oncol 16:114-9. 2004
  2. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, 4200 East Ninth Avenue, B 190, Denver, CO 80262, USA
    Cancer Chemother Biol Response Modif 20:197-225. 2002
  3. ncbi request reprint The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer
    Yago Nieto
    University of Colorado School of Medicine, Denver, CO 80262, USA
    Haematologica 88:201-11. 2003
  4. ncbi request reprint Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, Colorado 80262, USA
    Clin Cancer Res 10:2609-17. 2004
  5. ncbi request reprint Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program and Department of Pathology, University of Colorado, Denver, CO 80262, USA
    J Clin Oncol 20:707-18. 2002
  6. ncbi request reprint Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support
    Yago Nieto
    Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA
    Biol Blood Marrow Transplant 10:415-25. 2004
  7. ncbi request reprint Pharmacodynamics of high-dose chemotherapy
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Curr Drug Metab 2:53-66. 2001
  8. ncbi request reprint Status of high-dose chemotherapy for breast cancer: a review
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Biol Blood Marrow Transplant 6:476-95. 2000
  9. ncbi request reprint Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant
    Yago Nieto
    Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver, Colorado 80262, USA
    Clin Cancer Res 10:5076-86. 2004
  10. ncbi request reprint Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Biol Blood Marrow Transplant 6:198-203. 2000

Research Grants

Detail Information

Publications39

  1. ncbi request reprint High-dose chemotherapy for breast cancer: is another look warranted?
    Yago Nieto
    Blood and Marrow Transplant Program, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B 190 Denver, CO 80262, USA
    Curr Opin Oncol 16:114-9. 2004
    ..The authors review the main research results of high-dose chemotherapy for breast cancer in 2002 to 2003...
  2. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, 4200 East Ninth Avenue, B 190, Denver, CO 80262, USA
    Cancer Chemother Biol Response Modif 20:197-225. 2002
  3. ncbi request reprint The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer
    Yago Nieto
    University of Colorado School of Medicine, Denver, CO 80262, USA
    Haematologica 88:201-11. 2003
    ..In most cases, the results of these trials are premature and contradictory. Furthermore, they have often been interpreted, incorrectly in this author's judgment, as proof of lack of benefit of HDC...
  4. ncbi request reprint Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, Colorado 80262, USA
    Clin Cancer Res 10:2609-17. 2004
    ..dissected nodes), tumor size, hormone receptors, and HER2. In the present study we intended to test this model prospectively in a second patient cohort. In addition, we analyzed the long-term overall outcome of our HDC trials...
  5. ncbi request reprint Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program and Department of Pathology, University of Colorado, Denver, CO 80262, USA
    J Clin Oncol 20:707-18. 2002
    ..To study prognostic factors after high-dose chemotherapy (HDC) for patients with stage IV oligometastatic breast cancer...
  6. ncbi request reprint Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support
    Yago Nieto
    Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA
    Biol Blood Marrow Transplant 10:415-25. 2004
    ..2). In multivariate analyses, the presence of OTCs had an independent adverse effect on outcome in HRPBC, but not MBC. Our observations imply a direct role of OTCs in posttransplantation relapse in HRPBC...
  7. ncbi request reprint Pharmacodynamics of high-dose chemotherapy
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Curr Drug Metab 2:53-66. 2001
    ..We will summarize the observations from other authors and our own, on drugs employed at high doses, such as cyclophosphamide, melphalan, busulfan, carmustine, paclitaxel, or docetaxel...
  8. ncbi request reprint Status of high-dose chemotherapy for breast cancer: a review
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Biol Blood Marrow Transplant 6:476-95. 2000
    ..This may come through incorporating more active drugs into HDCT regimens and combining HDCT with novel strategies aimed at eradication of posttransplantation minimal residual disease...
  9. ncbi request reprint Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant
    Yago Nieto
    Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver, Colorado 80262, USA
    Clin Cancer Res 10:5076-86. 2004
    ....
  10. ncbi request reprint Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Biol Blood Marrow Transplant 6:198-203. 2000
    ..001) and advanced age (P = .01) were independent predictors of an increased risk of the appearance of this complication. No pharmacodynamic correlation was observed between any of the 3 drugs and cardiac toxicity...
  11. ncbi request reprint Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation
    Y Nieto
    University of Colorado Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver 80262, USA
    J Clin Oncol 18:2070-80. 2000
    ..To ascertain the predictive value of Her-2/neu overexpression and p53 mutations, assessed by immunohistochemistry, in high-risk primary breast cancer (HRPBC) treated with high-dose chemotherapy (HDCT)...
  12. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow, Transplant Program, Denver 80262, USA
    Cancer Chemother Biol Response Modif 21:171-209. 2003
  13. ncbi request reprint Stem-cell transplantation for the treatment of advanced solid tumors
    Yago Nieto
    University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B 190, Denver, CO 80262, USA
    Springer Semin Immunopathol 26:31-56. 2004
    ..This article reviews the results of the main phase II and III studies of HDC with ASCT, as well as the preliminary experience using allogeneic transplantation for solid tumors...
  14. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, CO 80262, USA
    Cancer Chemother Biol Response Modif 22:163-203. 2005
  15. ncbi request reprint Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, CO, USA
    Am J Clin Oncol 28:248-54. 2005
    ..The debate about the age effect in this population remains unsettled...
  16. ncbi request reprint Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer
    Yago Nieto
    Bone Marrow Transplant Program and Department of Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Cancer Res 10:7136-43. 2004
    ....
  17. ncbi request reprint A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant
    Y Nieto
    Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA
    Clin Cancer Res 5:3425-31. 1999
    ..This model can identify two subgroups of HRPBC patients with low (12%) and high (65%) risk for recurrence after HDCT. Future research that tests new therapies will focus on those patients with a high score...
  18. ncbi request reprint Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, Colorado, USA
    Biol Blood Marrow Transplant 11:297-306. 2005
    ..The notable activity of this regimen in treatment-refractory patients warrants its further evaluation...
  19. ncbi request reprint High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer
    P J Cagnoni
    Bone Marrow Transplant Program and Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver 80262, USA
    J Clin Oncol 16:1661-8. 1998
    ..To evaluate the feasibility of high-dose chemotherapy (HDC) with autologous hematopoietic progenitor-cell support (AHPCS) as part of combined modality therapy (CMT) in patients with inflammatory breast cancer (IBC)...
  20. ncbi request reprint Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Clin Cancer Res 5:1731-7. 1999
    ..These results warrant prospective randomized trials with a HDC-containing arm in this patient population...
  21. ncbi request reprint Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Clin Cancer Res 5:747-51. 1999
    ..Thus, in this combination, measurement of levels of parent CPA, with the objective of real-time therapeutic monitoring of this drug, is not informative...
  22. ncbi request reprint Transplantation of ex vivo expanded cord blood
    Elizabeth J Shpall
    University of Colorado Adult Bone Marrow Transplant Program, Denver, USA
    Biol Blood Marrow Transplant 8:368-76. 2002
    ..This study demonstrates that the CD34 selection and ex vivo expansion of CB prior to transplantation of CB is feasible. Additional accrual will be required to assess the clinical efficacy of expanded CB progenitors...
  23. ncbi request reprint Autologous stem-cell transplantation for solid tumors in adults
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, USA
    Hematol Oncol Clin North Am 13:939-68, vi. 1999
    ..This article reviews the results of HDC in different diseases and depicts potential directions of future progress...
  24. ncbi request reprint Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer
    I McNiece
    BMT Program, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Blood 96:3001-7. 2000
    ....
  25. ncbi request reprint Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant
    S L Rosinski
    Bone Marrow Transplant Program, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Bone Marrow Transplant 36:425-30. 2005
    ..These observations suggest the feasibility of prospective identification of those patients at higher risk of relapse, based on their immune status...
  26. ncbi request reprint Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study
    J A Gutman
    Department of Medicine, Bone Marrow Transplantation Program, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Bone Marrow Transplant 36:443-51. 2005
    ....
  27. ncbi request reprint Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, CO 80262, USA
    Bone Marrow Transplant 28:1083-6. 2001
    ..A rapid response was achieved. Chemotherapy did not cause an obvious compromise of donor stem cell engraftment or establishment of stable donor chimerism...
  28. ncbi request reprint Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Bone Marrow Transplant 23:1323-4. 1999
    ..This patient was included in a clinical trial of high-dose chemotherapy (HDCT) with HLA-matched peripheral SCT for metastatic breast cancer. She expired 53 days after transplantation from organ failure unrelated to her CMV oophoritis...
  29. ncbi request reprint Acute renal failure after nonmyeloablative hematopoietic cell transplantation
    Chirag R Parikh
    Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Am Soc Nephrol 15:1868-76. 2004
    ..The data are also suggestive that ARF may contribute to mortality after nonmyeloablative HCT...
  30. ncbi request reprint Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia
    B C Medeiros
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    Bone Marrow Transplant 31:1053-5. 2003
    ..On day +190, refractory lactic acidosis followed by fatal cardiovascular collapse developed, without evidence of infection. Data from this case demonstrates that NST may correct the erythropoietic defect of CSA...
  31. ncbi request reprint Acute encephalopathy: a new toxicity associated with high-dose paclitaxel
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA
    Clin Cancer Res 5:501-6. 1999
    ..Paclitaxel-containing high-dose chemotherapy can cause severe acute encephalopathy. An aggravating effect from prior brain irradiation or concurrent 1,3-bis(2-chloroethyl)-1-nitrosourea seems possible...
  32. ncbi request reprint Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1324-37. 2007
    ..The resulting gemcitabine/docetaxel/melphalan/carboplatin combination was highly active in refractory cancers and should be further tested in disease-specific trials...
  33. ncbi request reprint Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4405-13. 2007
    ..We hypothesized that EGFR status plays a major prognostic role in this setting, through expression, activation, or the presence of its mutated variant EGFRvIII...
  34. ncbi request reprint Docetaxel administered during pregnancy for inflammatory breast carcinoma
    Yago Nieto
    Department of Medical Oncology, University of Navarra, Pamplona, Spain
    Clin Breast Cancer 6:533-4. 2006
    ..After delivery of a healthy child, she underwent surgery, which showed tumor downstaging to pT0 N2, followed by radiation therapy and hormone therapy. This report suggests the safety of docetaxel after the first trimester of pregnancy...
  35. ncbi request reprint Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation
    Yago Nieto
    Bone Marrow Transplant Programs, University of Navarra, Pamplona, Spain
    Biol Blood Marrow Transplant 12:217-25. 2006
    ..5%, 50%, and 40%, respectively. In conclusion, the use of tacrolimus/MMF after MSD NST is associated with encouraging rates of GVHD control...
  36. ncbi request reprint A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects
    Roy B Jones
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 10:276-82. 2004
    ..Further, we suggest that amifostine use with BCNU in other contexts and with clinically achievable doses is unlikely to protect the lung from BCNU-associated acute injury...
  37. ncbi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review
    Denise M Oliansky
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 14:137-80. 2008
    ..conventional conditioning in older (>60 years) and intermediate (40-60 years) aged adults? (4) What is the impact on survival outcomes of unrelated donor HSCT vesus chemotherapy in younger (<40 years) adults with high risk disease?..
  38. ncbi request reprint Prognostic value of nodal ratios in node-positive breast cancer
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:2910-6. 2006
    ..Here we examine the data supporting the use of nodal ratios in breast cancer prognosis and consider the potential advantages and disadvantages of including nodal ratios in breast cancer staging...
  39. ncbi request reprint The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation
    Roy Jones
    Biol Blood Marrow Transplant 11:819-22. 2005

Research Grants1

  1. Prognostic Modeling of High-Risk Primary Breast Cancer
    Yago Nieto; Fiscal Year: 2003
    ..abstract_text> ..